Advanced CSCC can be an especially aggressive disease and has had historically limited treatment options1

CSCC is one of the most common cancers worldwide and the second-most common type of skin cancer in the US2-4

  • CSCC incidence is expected to increase 2% to 4% each year5
  • US incidence has increased substantially, by 50% to 200%, over the past 3 decades6
  • Risk factors for developing CSCC include:
    • Ultraviolet (UV) radiation exposure7,8
    • Ionizing radiation exposure8
    • Male gender7
    • Advanced age (>65 years)7,9
    • Fair or light skin7
    • Immunosuppression7
  • Anatomic locations that are exposed to the sun, including the head, neck, and extremities, are common sites of CSCC7
Historically, patients with advanced CSCC have lacked FDA-approved treatment options.10,11
About LIBTAYO
  1. Jennings L et al J Clin Aesthet Dermatol. 2010;3(4):39-48.
  2. Gurudutt VV et al [published online February 21, 2011]. J Skin Cancer. 2011;2011:502723. doi:10.1155/2011/502723
  3. Parikh SA et al [published online August 1, 2014]. F1000Prime Rep. 2014;6:70. doi:10.12703/P6-70
  4. Lomas A et al. Br J Dermatol. 2012;166(5):1069-1080.
  5. Burton KA et al [published online June 29, 2016]. Am J Clin Dermatol. 2016;17(5):491-508. doi:10.1007/s40257-016-0207-3
  6. Karia PS et al. J Am Acad Dermatol. 2013;68(6):957-966.
  7. Califano JA et al. In: Amin MB et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:171-181.
  8. Kauvar ANB et al. Dermatol Surg. 2015;41(11):1214-1240.
  9. Garcovich S et al. Aging Dis. 2017;8(5):643-661.
  10. Ribero S et al. Curr Opin Oncol. 2017;29(2):129-135.
  11. Stratigos A et al. Eur J Cancer. 2015;51(14):1989-2007.